Patient profiles

Demographics:

• 59-year-old male
• Works as an accountant
• Lives in the city with his wife and has three children in university
• Sees an oncologist at a tertiary centre close to home (about 25 minutes away)
• Enjoys cycling and sailing as well as travelling with his wife
• No significant comorbidities

MM history:

• Diagnosed with MM 5 years ago
• Standard-risk cytogenetics
• ECOG performance status = 0
• ISS stage = I

First-line treatment (transplant-eligible):

• RVd induction
• ASCT
• R maintenance for 5 years

Would you consider BLENREP in combination therapy for Bryant?

ASCT: autologous stem cell transplant; ECOG: Eastern Cooperative Oncology Group; ISS: International Staging System; MM: multiple myeloma; R maintenance: lenalidomide maintenance; RVd: lenalidomide + bortezomib and dexamethasone.

Demographics:

• 67-year-old female
• Recently retired and enjoys writing
• Lives just outside the city with her husband
• Her oncologist is at a community hospital 30 minutes away
• Enjoys nature walks, volunteering in the community, and visits her children and grandchildren abroad
• Comorbidities include:
• Long-standing hypertension with mild diastolic dysfunction
• Stage 3 CKD (eGFR ~45 mL/min/1.73m²)
• Mild cataract in one eye, which is under observation

MM history:

• Diagnosed with MM 4 years ago
• High-risk cytogenetics
• ECOG performance status = 0
• ISS stage = I

First-line treatment (transplant-ineligible):

• DRd

Would you consider BLENREP in combination therapy for Bonnie?

ECOG: Eastern Cooperative Oncology Group; ISS: International Staging System; MM: multiple myeloma; DRd: daratumumab + lenalidomide + dexamethasone.

Demographics:

• 70-year-old female
• Retired administrative assistant
• Lives alone in a small rural town and receives support from her children and grandchildren living nearby
• Drives over an hour into the city for her appointments at a tertiary centre
• Enjoys painting and going to weekly water aerobic classes
• Has type 2 diabetes and CKD (eGFR 50 mL/min/1.73m²)

MM history:

• Diagnosed with MM 8 years ago
• Standard-risk cytogenetics
• ECOG performance status = 1
• ISS stage = II

First-line treatment (transplant-eligible):

• CyBorD induction
• ASCT
• R maintenance

Second-line treatment:

• IsaKd

Could BLENREP in combination therapy be an option for Beatrice?

ASCT: autologous stem cell transplant; CKD: chronic kidney disease; CyBorD: cyclophosphamide + bortezomib + dexamethasone; ECOG: Eastern Cooperative Oncology Group; IsaKd: isatuximab + carfilzomib + dexamethasone; ISS: International Staging System; MM: multiple myeloma; R maintenance: lenalidomide maintenance.